Jasmy My Genome Guard and the role of blockchain in personalised medicine

The three project partners. Official image supplied by Jasmy in its 27 November 2023 announcement. Logos belong to their respective owners. [1]

Jasmy’s My Genome Guard project gives its personal data technology a specific role in healthcare: managing genomic information while supporting research into personalised cancer treatment. It also includes a defined use for Jasmy tokens through participant payments. The project brings together Jasmy, Novacellum and Biomedica Solution, combining expertise in data management, genomic research and peptide manufacturing.

There is also a confirmed 2026 milestone. On 24 April 2026 both medical partners announced that the project had entered full operation that financial year. That takes the story beyond its original announcement, although published enrolment numbers, revenue and payment volumes are still needed to assess its scale.

For those following #Jasmy, the project deserves attention because it makes the company’s ideas about personal data easier to understand. It offers a practical example of how sensitive information, permission to use it and participant benefits can be managed together.

What My Genome Guard does

The project supports whole-genome analysis and the development of a cancer immunotherapy called CTC neoantigen dendritic cell therapy. Its website describes genetic testing through the Green Chord service, with participating medical institutions explaining relevant results to members. Member information and genomic analysis information are managed through Jasmy’s Personal Data Locker, or PDL.

There are two related activities here. One is the analysis and management of participants’ genetic information. The other is support for a particular approach to cancer treatment if a participant later becomes eligible under the project’s conditions. Joining the project should not be read as a promise that someone will avoid cancer or benefit from a particular treatment.

• Jasmy supplies the information technology.

• Novacellum develops the medical approach and works with medical institutions.

• Biomedica Solution manufactures the personalised neoantigen peptides used in the treatment.

Keeping these responsibilities clear helps explain what Jasmy contributes and where medical decisions sit.

The personalised treatment explained

The terminology sounds complicated, but the underlying research idea is understandable. CTCs are circulating tumour cells: cancer cells found in the bloodstream. Neoantigens are distinctive markers arising from changes in cancer cells, and these markers can differ between patients. Novacellum’s approach aims to identify suitable markers and use them in an immune treatment involving dendritic cells, which help the immune system recognise targets.

An accessible way to think about it is that the treatment seeks to give the immune system information about the particular cancer it needs to recognise. That is why the genetic analysis and the handling of the resulting information matter to the project.

The research should also be described at the right level. In November 2025, Novacellum highlighted a published study examining circulating tumour cells from 11 people with advanced cancer and identifying candidate neoantigens.

The company explicitly said the research explored the possibility of understanding individual cancers without obtaining tumour tissue; it did not directly determine clinical care or treatment decisions.

That is evidence of research activity. It does not establish that My Genome Guard has demonstrated improved survival or that every participant can receive effective treatment. Those would require different clinical evidence.

Why genomic information needs careful management

The value of the project for Jasmy becomes clearer when the focus shifts to the information involved. Genomic research requires people and organisations to work with highly sensitive material, while participants need to understand who can access it and how it is being used.

Jasmy’s 2023 technical announcement described an enhanced PDL, provisionally called Super PDL. Its proposed features included access requiring permission from both the individual and specified medical parties, separating genomic information from directly identifying information, retaining traceability and accommodating large datasets.

This is a more demanding task than giving someone a folder in cloud storage. A useful system has to connect a person to their rights while limiting unnecessary disclosure of identity and health information to others.

In its December 2024 development account, Jasmy described adding servers and control functions linked to blockchain. It also reported obtaining ISMS certification in April 2024. These are company-reported implementation milestones; they should not be treated as proof that any system is immune to security failures.

Jasmy’s original PDL illustration. The four functions shown are safe storage, permission-based sharing, monitoring for unintended use and sharing abstracted data without identifying the person. Japanese original. Source: Jasmy, PR TIMES STORY, 3 December 2024.

What blockchain contributes

The published design uses blockchain as part of a wider information-management system. Jasmy describes traceability, digital membership rights and mechanisms for participant payments. Its materials do not establish that complete, readable genome files are published on a public blockchain.

The practical question is whether the system can maintain a reliable connection between permission, information use and the benefits a participant is entitled to receive. For example, a research organisation may need access to authorised information without needing the participant’s name. A payment process may need to confirm that a person holds membership rights without publicly exposing their medical records.

Those examples explain the potential usefulness of the architecture. They are not independent verification that every part of the published design is operating at scale.

The project website also describes an NFT as evidence of participation rights. Here, the NFT’s stated purpose is to represent membership benefits and entitlements. Readers should not infer that it is a separately valuable collectible or that holding it gives ownership of the underlying medical technology.

Where JASMY tokens fit

My Genome Guard has an explicit connection to the token. Jasmy’s original announcements describe token payments for eligible information contributions and a conditional research-support payment called Mutual Aid Payment, or MAP. They also describe retaining Jasmy tokens corresponding to part of the participation fees to support the assistance arrangement.

The published first-round membership terms provide a concrete detail: a one-time MAP payment of 123,526 JMY, subject to the stated eligibility conditions. The same terms specify a membership period ending on 31 March 2030 and cap membership at 1,000 people. JMY is the notation used in those Japanese materials for Jasmy Coin. These are first-round contractual provisions, not evidence that the maximum membership has been reached.

This makes the token connection more specific than an assumption that every use of Jasmy software automatically requires customers to buy JASMY. Here, the project documents actually name token-based participant benefits.

However, a payment denominated in tokens does not by itself reveal how many tokens must be bought on an exchange, when they are acquired or how long recipients keep them. Those details matter when assessing market demand. Paying a participant transfers tokens; it does not automatically remove them permanently from circulation.

What participants are actually promised

The project website describes conditional peptide-manufacturing support and MAP assistance for qualifying members. It also states that the therapy is paid care outside public insurance coverage. The support should therefore not be described as free comprehensive cancer treatment.

The first-round terms make the conditions material. The MAP provision depends on peptide synthesis being completed and approved treatment beginning at a designated medical institution. The accompanying disclosures also warn that payment quantities may be reduced if Jasmy’s business or financial circumstances change and say that protection through an insurance policyholder protection organisation is unavailable.

These details matter because they prevent membership benefits being mistaken for an unconditional medical or financial guarantee. A digital certificate records rights under an agreement; the agreement still determines what those rights mean.

Jasmy’s original treatment-support and MAP illustration. It connects the member, Novacellum, designated medical institutions, Biomedica Solution and Jasmy. The arrows show referral, sampling, peptide manufacture, treatment, information storage and assistance payment. Japanese original; the illustration does not replace the membership conditions. Source: Jasmy, PR TIMES STORY, 3 December 2024. [3]

What changed in 2026

The project was announced on 27 November 2023. Jasmy published a detailed development account on 3 December 2024, and the project website lists an initial recruitment period running from 2 December 2024 to 31 March 2025. [1, 3, 4]

The partner announcements dated 24 April 2026 then confirmed full operation that financial year. Their wording supports an operational milestone, but the short notices do not provide enrolment totals, revenue, numbers treated or token-payment volumes.

This chronology matters when the project appears on social media. It is reasonable to discuss its continuing relevance in 2026. It would be misleading to present the original partnership as a brand-new October announcement, or to infer that the older recruitment dates establish that applications remain open today.

Why it matters to the wider Jasmy business

My assessment is that the project’s strongest strategic value lies in the capabilities Jasmy develops and demonstrates through it. A system that manages sensitive information, distinct permissions and participant entitlements could have applications beyond this particular programme. That possibility depends on further deployments and commercial demand.

Jasmy’s own December 2024 account adds useful context. The company acknowledged that the project’s economics were difficult from its perspective, while describing the PDL development and security-management work as valuable outcomes. That was a historical assessment, not a current financial statement, but it argues against assuming the initiative was already a major profit centre.

For investors, three questions therefore need separate answers.

• Does the technology solve a useful problem?

• Can Jasmy earn sustainable revenue from delivering it?

• Does that activity create meaningful, recurring demand for JASMY?

Progress on the first question is encouraging, but it does not settle the other two.

The evidence to watch next

The next useful update would provide measurable adoption. Confirmed participant numbers would show how far the programme has progressed. The number of completed genomic analyses or participating medical institutions would help establish the extent of delivery.

Financial disclosure would answer a different question: whether the project generates revenue for Jasmy and how delivery costs compare with that income. Token reporting would be useful too, particularly aggregate payment volumes, the source of tokens and any disclosed reserve arrangements.

Medical outcomes require their own evidence. Published research, clearly described study methods and clinical results would be more informative than broad claims about a cancer breakthrough. Commercial success and clinical effectiveness must each be assessed on their own evidence.

My Genome Guard gives Jasmy a documented role in a healthcare programme with an explicit token component. I see a credible reason to follow its progress.

The next step in assessing its importance is evidence showing how widely it is used, what it earns and how the token mechanism functions in practice.

Sources

Japanese primary sources checked on 21 October 2026. English descriptions are paraphrases. The project website and terms were available through indexed search extracts; direct retrieval was restricted. First-round terms are identified as such throughout and are not represented as newly issued 2026 terms.

[1] Jasmy partnership announcement, 27 November 2023. Read source

[2] Jasmy technical and payment-design announcement, 27 November 2023. Read source

[3] Jasmy development account, 3 December 2024. Read source

[4] Official My Genome Guard project website. Read source

[5] Published first-round membership terms, established 2 December 2024, especially articles 1, 7 and 12 and the pre-contract disclosures. Read source

[6] Novacellum full-operation announcement, 24 April 2026. Read source

[7] Biomedica Solution full-operation announcement, 24 April 2026. Read source

[8] Novacellum explanation of neoantigens and its treatment approach. Read source

[9] Novacellum research notice, 25 November 2025. Read source

This is an independent Jasmy Australia article, unaffiliated with Jasmy Corporation. It discusses the project and its investment relevance and does not recommend medical treatment or an investment.